Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

CMPDI IPO: Powering India’s Mining Growth Story

IPM Pharma Pulse March-25: Driven by Semaglutide Generics; Low Single Digit Growth Outlook for FY27

Indian Flexible Workspaces: A Strategic Comparative Analysis of Market Leaders

EV(E2W) Market Share War: Who Will Gain From the Consolidating Market?

Anthropic's Claude Code: Overnight Disruption to IBM's Legacy

From Headcount to Agents: Structural Change in Indian IT Industry

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

India Health care / Thematic (Sector/Industry)

Akums Drugs and Pharmaceuticals (0200361D IN)

<ul>
<li>India's CDMOs are tripling capacity and pivoting to peptides, ADCs, and drug-device combinations as global pharma outsources complex drug development.</li>
<li>The GLP-1 boom, BIOSECURE Act, and a $64 billion addressable market are redirecting multi-year manufacturing mandates toward Indian CRDMO platforms.</li>
<li>Firms investing in science-led infrastructure will command structurally higher margins, those adding only volume face commoditisation and multiple compression ahead.</li>
</ul>


India's CDMOs are tripling capacity and pivoting to peptides, ADCs, and drug-device combinations as global pharma outsources complex drug development.
The GLP-1 boom, BIOSECURE Act, and a $64 billion addressable market are redirecting multi-year manufacturing mandates toward Indian CRDMO platforms.
Firms investing in science-led infrastructure will command structurally higher margins, those adding only volume face commoditisation and multiple compression ahead.


CDMO 군비 경쟁: 인도가 조용히 세계의 제약 공장으로 거듭나는 과정